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Abstract: This research investigated the effect of enzymatically digested low molecular 
weight (MW) chitosan oligosaccharide on type 2 diabetes prevention. Three different 
chitosan oligosaccharide samples with varying MW were evaluated in vitro for inhibition 
of rat small intestinal α-glucosidase and porcine pancreatic α-amylase (GO2KA1; <1000 Da, 
GO2KA2; 1000–10,000 Da, GO2KA3; MW > 10,000 Da). The in vitro results showed that 
all tested samples had similar rat α-glucosidase inhibitory and porcine α-amylase inhibitory 
activity. Based on these observations, we decided to further investigate the effect of all 
three samples at a dose of 0.1 g/kg, on reducing postprandial blood glucose levels in 
Sprague-Dawley (SD) rat model after sucrose loading test. In the animal trial, all tested 
samples had postprandial blood glucose reduction effect, when compared to control, 
however GO2KA1 supplementation had the strongest effect. The glucose peak (Cmax) for 
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GO2KA1 and control was 152 mg/dL and 193 mg/dL, respectively. The area under the 
blood glucose-time curve (AUC) for GO2KA1 and control was 262 h mg/dL and  
305 h mg/dL, respectively. Furthermore, the time of peak plasma concentration of blood 
glucose (Tmax) for GO2KA1 was significantly delayed (0.9 h) compared to control  
(0.5 h). These results suggest that GO2KA1 could have a beneficial effect for blood 
glucose management relevant to diabetes prevention in normal and pre-diabetic individuals. 
The suggested mechanism of action is via inhibition of the carbohydrate hydrolysis enzyme 
α-glucosidase and since GO2KA1 (MW < 1000 Da) had higher in vivo effect, we hypothesize 
that it is more readily absorbed and might exert further biological effect once it is absorbed 
in the blood stream, relevant to blood glucose management. 
Keywords: type 2 diabetes; pre-diabetes; blood glucose; α-glucosidase inhibition;  
low molecular chitosan oligosacharide; GO2KA1 
 
1. Introduction  
Diabetes is a group of diseases marked by high levels of blood glucose resulting from defects in 
insulin production, insulin action, or both [1]. Type 2 diabetes accounts for about 90% to 95% of all 
diagnosed cases of diabetes in adults [1]. Pre-diabetes is a condition in which individuals have blood 
glucose levels higher than normal but not high enough to be classified as diabetes [2]. Pre-diabetic 
people have an increased risk of developing type 2 diabetes, heart disease, and stroke [3–5]. At least 
220 million people worldwide have diabetes and this figure is likely to double by 2030 [6]. In the 
United States, in 2007, 23.7 million people (10% of American adults) had diabetes and by 2050 this 
figure is expected to jump to 33%, or one-third of all American adults [1]. It is important to recognize 
that optimal diet-induced prevention of type 2 diabetes onset is an effective strategy to reduce the 
expected increases in morbidity and cost associated with treatment of diabetes. 
The major source of blood glucose is dietary carbohydrates that are initially hydrolyzed by 
pancreatic α-amylase, followed by α-glucosidase before being absorbed in the small intestine [7]. 
Reduction of the elevated postprandial blood glucose level is an established strategy for management 
of type 2 diabetes [8]. Inhibition of carbohydrate hydrolyzing enzymes, using α-glucosidase inhibitors 
such as Acarbose, is one way to achieve this strategy [8]. Recent studies showed that phenolic 
phytochemicals from botanical sources are natural inhibitors of α-amylase and α-glucosidase [9–12] 
and thus can be used to manage postprandial hyperglycemia with minimal side effects [9–11]. 
Chitosan is commercially obtained by the deacetylation of chitin, the most abundant natural 
biopolymer on earth after cellulose. Despite chitosan’s well-recognized beneficial effects for 
hypertension [13], cholesterol [14] and weight-loss [15] management, chelation of some metal ions 
from dietary sources becomes unfavorable for human nutrition [16]. However, these side-effects do not 
exist with low molecular weight chitosan oligosaccharide, resulting from the enzymatic digestion of 
chitosan, mainly because low molecular weight chitosan oligosaccharide can be readily absorbed into 
the bloodstream [16]. 
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Low molecular weight chitosan oligosaccharide has been shown to have many health  
beneficial biological activities including antifungal [16], antibacterial [17–19], antitumor [20,21],  
immuno-enhancing [22], anti-hypertension via ACE-I inhibition [13] and protective effects against 
infection [23]. Additionally, Kondo and others [24] showed that low molecular weight chitosan 
oligosaccharide can prevent the progression of diabetes in streptozotocin-induced diabetic mice. 
Recently, Kim and others [25] clinically demonstrated the blood glucose lowering effect of low 
molecular weight chitosan oligosaccharide in healthy human subjects.  
Both published studies [24,25] that investigated the effect of low molecular weight chitosan 
oligosaccharide for type 2 diabetes reported the observed effect without investigation the mechanism 
of action, which is very important for the design of more vigorous clinical studies. In this study,  
in vitro screening is used to determine the effect of different low molecular weight chitosan 
oligosaccharides (in terms of MW) on the inhibition of carbohydrate hydrolysis enzymes. Then all 
samples were further assayed in vivo in SD rats model for postprandial blood glucose level reduction 
after sucrose loading test, to further confirm the observed in vitro findings.  
2. Results and Discussion  
2.1. Rat α-Glucosidase and Porcine α-Amylase Assay 
All tested samples had dose-dependent and similar rat α-glucosidase inhibitory activity (Figure 1). 
These results indicate that the molecular weight of enzymatically digested chitosan oligosaccharide 
does not influence the inhibition of α-glucosidase (Figure 1). In the case of α-amylase inhibition, we 
observed that all the samples had significantly lower inhibitory activity, when compared to α-glucosidase 
inhibition (Figure 2). Similarly to α-glucosidase, it appears that the molecular weight differences do 
not influence the inhibitory effect of enzymatically digested chitosan oligosaccharide on α-amylase 
(Figure 2). 
This is the first report of α-glucosidase inhibitory effect of low molecular weight chitosan 
oligosaccharide. Our results present a strong α-glucosidase inhibitory effect of all samples, regardless 
of MW, and a significantly lower α-amylase inhibitory activity. Previous reports have indicated that 
plant derived phenolic phytochemicals have lower α-amylase inhibitory activity and a stronger 
inhibition activity against α-glucosidase [10,11]. The main side effects of type 2 diabetes control 
drugs, such as Acarbose, are abdominal distention, flatulence, meteorism and possibly diarrhea [26]. It 
has been suggested that such adverse effects might be caused by the excessive inhibition of pancreatic 
α-amylase resulting in the abnormal bacterial fermentation of undigested carbohydrates in the  
colon [26,27]. Our observation of lower in vitro α-amylase inhibitory activity suggests that the extent 
of the side effects (if any) will be less than Acarbose. 
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Figure 1. Dose dependent changes in rat intestinal α-glucosidase inhibitory activity  
(% inhibition) of chitosan oligosaccharides classified by molecular weight (GO2KA1;  
MW < 1000 Da, GO2KA2; MW 1000–10,000 Da, GO2KA3; MW > 10,000 Da). The 
results represent the mean ± S.D. of values obtained from three measurements. Different 
corresponding letters indicate significant differences at p < 0.05 by Duncan’s test. A−C First 
letter is among different samples and a−c second one is among different concentrations 
within same samples. 
 
Figure 2. Dose dependent changes in porcine pancreas α-amylase inhibitory activity  
(% inhibition) of chitosan oligosaccharides classified by molecular weight (GO2KA1;  
MW < 1000 Da, GO2KA2; MW 1000–10,000 Da, GO2KA3; MW > 10,000 Da). The 
results represent the mean ± S.D. of values obtained from three measurements. Different 
corresponding letters indicate significant differences at p < 0.05 by Duncan’s test. A−C First 
letter is among different samples and a−c second one is among different concentrations 
within same samples. 
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2.2. Sucrose Loading Test in SD Rat Model 
To further confirm the actual in vivo relevance of our in vitro findings that enzymatically digested 
chitosan oligosaccharide has α-glucosidase inhibitory effect regardless of MW, we performed a 
sucrose loading test in SD Rat, which is more relevant towards type 2 diabetes incidence prevention 
with normal or pre-diabetic individuals, rather than type 2 diabetes treatment. 
Our results show that all tested samples (0.1 g/kg) result in lower blood glucose peaks when 
compared to control, however higher when compared to the known type 2 diabetes drug and  
α-glucosidase inhibitor, Acarbose (0.005 g/kg) (Figures 3–5). When we calculated the more precise 
pharmacodynamics of the three tested samples (Table 1), it was clear that all treatments had better 
effect in terms of blood glucose peak (Cmax), area under the curve, which represents the total amount of 
glucose in blood (AUCmax) and the time of the observed blood glucose peak (Tmax), when compared to 
control (Table 1). Reduced blood glucose peak results in lower glucose stress that is observed after 
meals. Reduced AUCmax indicates that either less glucose is absorbed in the blood or that glucose is 
more efficiently utilized when in the blood (via glucose uptake and further utilization in muscle and fat 
cells), or both. Finally, the retardation of Tmax, indicated slower absorption of glucose in the blood, 
which could be due to the observed in vitro α-glucosidase inhibitory effects. 
Figure 3. Effect of GO2KA1 on sucrose loading test. After fasting for 24 h, six-week-old, 
male SD rats were orally administered with sucrose solution (2.0 g/kg) with or without 
samples (GO2KA1; MW < 1000 Da, positive control; Acarbose). Each point represents 
mean ± S.D. (n = 5). A−C Different corresponding letters indicate significant differences  
(p < 0.05) at 0.5 h by Duncan’s test. a−c Different corresponding letters indicate significant 
differences (p < 0.05) at 1.0 h by Duncan’s test.  
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More close evaluation of our findings suggests that GO2KA1 and GO2KA3 result in greater 
reduction of AUCmax when compared to GO2KA2. Overall, GO2KA1 administration resulted in lower 
Cmax and AUCmax values when compared to GO2KA3, but this difference was not statistically 
different. However, GO2KA1 administration reduced the blood glucose levels after 1 h by 14.3% 
(compared to control) while GO2KA3 administration resulted to a reduction around 4% (compared to 
control (Figures 3 and 5).  
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Figure 4. Effect of GO2KA2 on sucrose loading test. After fasting for 24 h, six-week-old, 
male SD rats were orally administered with sucrose solution (2.0 g/kg) with or without 
samples (GO2KA2; MW 1000–10,000 Da, positive control; Acarbose). Each point 
represents mean ± S.D. (n = 5). A−C Different corresponding letters indicate significant 
differences (p < 0.05) at 0.5 h by Duncan’s test. a−c Different corresponding letters indicate 
significant differences (p < 0.05) at 1.0 h by Duncan’s test.  
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Our findings suggest that all samples have potential for lowering postprandial blood glucose levels 
after meal, which is relevant to type 2 diabetes incidences. Additionally, our observations, that the 
effect is milder when compared to Acarbose, a known drug for type 2 diabetes treatment, indicates that 
low molecular weight chitosan oligosaccharide can be ideal for type 2 diabetes prevention in normal 
and pre-diabetic individuals that do not need to use drug innovations that have severe side effects. 
Figure 5. Effect of GO2KA3 on sucrose loading test. After fasting for 24 h, six-week-old, 
male SD rats were orally administered with sucrose solution (2.0 g/kg) with or without 
samples (GO2KA3; MW > 10,000 Da, positive control; Acarbose). Each point represents 
mean ± S.D. (n = 5). A−C Different corresponding letters indicate significant differences  
(p < 0.05) at 0.5 h by Duncan’s test. a−c Different corresponding letters indicate significant 
differences (p < 0.05) at 1.0 h by Duncan’s test.  
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All enzymatically digested chitosan oligosaccharide tested samples had similar α-glucosidase 
inhibitory activities, which resulted in slower glucose absorption (as indicated with the similar Tmax 
values among tested samples), but GO2KA1 and GO2KA3 had better effect on AUCmax (Table 1). 
Additionally, GO2KA1 had better effect for type 2 diabetes prevention in SD rats, in terms of blood 
glucose reductions of after 1 h (Figures 3 and 5), resulting to a 14%, compared to the 4% reduction 
resulting from GO2KA3 administration. Previous reports show that low MW chitosan oligosaccharide 
is more readily absorbed in the bloodstream [28,29]. We believe that low molecular weight GO2KA1 
(<1000 Da) is more readily absorbed into the bloodstream when compared to the significantly larger 
GO2KA2 and GO2KA3 (MW 1000–10,000 Da and > 10,000 Da, respectively) and might have other 
possible effects towards aiding glucose absorption into muscle and fat cells. Thus, we can speculate 
that GO2KA1 might have a “dual” beneficial effect towards blood glucose management acting both in 
the gastrointestinal level, by inhibiting carbohydrate hydrolysis enzymes, as well as in the cellular 
level, after being absorbed into the bloodstream, by aiding towards the glucose absorption into muscle 
and fat cells. 
Table 1. Pharmacodynamic (PD) parameters of SD control rats or after administration of 
GO2KA1, GO2KA2, GO2KA3 and Acarbose after sucrose ingestion. 
Groups 
PD parameters 
AUClast (h·mg/dL) Cmax (mg/dL) Tmax (h) 
Sucrose Control 305.1 ± 7.3 A 193.0 ± 5.1 a 0.5 ± 0.0 
 Acarbose (5.0 mg/kg) 214.7 ± 15.2 B 118.8 ± 10.9 b 1.2 ± 0.8 
 GO2KA1 (0.1 g/kg) 262.4 ± 11.9 C 152.0 ± 6.3 c 0.9 ± 0.7 
  PD parameters 
  AUClast (h·mg/dL) Cmax (mg/dL) Tmax (h) 
Sucrose Control 306.8 ± 7.3 A 192.0 ± 8.8 a 0.6 ± 0.2 
 Acarbose (5.0 mg/kg) 226.1 ± 5.8 B 125.2 ± 7.0 b 0.9 ± 0.2 
 GO2KA2 (0.1 g/kg) 289.1 ± 10.1 A 167.0 ± 12.8 c 0.9 ± 0.2 
  PD parameters 
  AUClast (h·mg/dL) Cmax (mg/dL) Tmax (h) 
Sucrose Control 305.1 ± 7.3 A 193.0 ± 5.1 a 0.5 ± 0.0 
 Acarbose (5.0 mg/kg) 222.5 ± 17.8 B 116.4 ± 10.8 b 1.2 ± 0.8 
 GO2KA3 (0.1 g/kg) 268.3 ± 11.2 C 154.0 ± 9.2 c 0.7 ± 0.3 
A−C & a−c Different corresponding letters indicate significant differences at p < 0.05 by Duncan’s test. 
3. Experimental Section  
3.1. Materials  
Chitosan oligosaccharides classified by molecular weight (GO2KA1; MW < 1000 Da, GO2KA2; 
MW 1000–10,000 Da, GO2KA3; MW > 10,000 Da) were purchased from Kunpoong Bio Co. Ltd. 
(Seoul, Korea). Porcine pancreatic α-amylase (EC 3.2.1.1) and rat intestinal acetone powders of  
α-glucosidase (EC 3.2.1.20) were also purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 
Unless noted, all chemicals were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 
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3.2. α-Glucosidase Inhibition Assay 
To evaluate the potency of chitosan oligosaccharide s classified by molecular weight GO2KA1, 
GO2KA2, GO2KA3, the dose dependent inhibitory effect of the three selected samples on rat 
intestinal α-glucosidase was evaluated using different concentrations (between 5 and 20 mg/mL). Rat 
intestinal α-glucosidase assay referred to the method of Kwon et al. [10] with slight modification. A 
total of 0.1 g of rat-intestinal acetone powder was suspended in 3 mL of 0.9% saline, and the 
suspension was sonicated 12 times for 30 s at 4 °C. After centrifugation (10,000g, 30 min, 4 °C), the 
resulting supernatant was used for the assay. Sample solution (50 μL) and 0.1 M phosphate buffer  
(pH 6.9, 100 μL) containing glucosidase solution (1.0 U/mL) was incubated at 25 °C for 10 min. After  
pre-incubation, 5 mM p-nitrophenyl-α-D-glucopyranoside solution (50 μL) in 0.1 M phosphate buffer 
(pH 6.9) was added to each well at timed intervals. The reaction mixtures were incubated at 25 °C for 
5 min. Before and after incubation, absorbance was read at 405 nm and compared to a control, which 
had 50 μL of buffer solution in place of the extract by micro-plate reader (SUNRISE; Tecan Trading 
AG, Saltzburg, Austria). The α-glucosidase inhibitory activity was expressed as inhibition % and was 
calculated as follows (1): 
  100(%) Inhibition 405 405405 







 Control
ExtractControl
A
AA
 (1)
3.3. a-Amylase Inhibition Assay 
To evaluate the potency of chitosan oligosaccharide s classified by molecular weight (GO2KA1, 
GO2KA2, GO2KA3) the dose dependent inhibitory effect of the three selected samples on rat 
intestinal α-amylase was evaluated using different concentrations (between 5 and 20 mg/mL). Porcine 
pancreatic α-amylase inhibition referred to the method of Kwon et al. [10]. Sample solution (200 μL) 
and 0.02 M sodium phosphate buffer (pH 6.9 with 0.006 M sodium chloride, 500 μL) containing  
α-amylase solution (0.5 mg/mL, 5.0 mU/mL) were incubated at 25 °C for 10 min. After  
pre-incubation, 500 μL of a 1% starch solution in 0.02 M sodium phosphate buffer was added. The 
reaction mixture was then incubated at 25 °C for 10 min. The reaction was stopped with 1.0 mL of 
dinitrosalicylic acid (DNS) and incubation in a boiling water bath for 5 min, followed by cooling down 
to room temperature. The reaction mixture was then diluted after adding distilled water, and 
absorbance was measured at 540 nm (2) with ELISA micro-plate reader (SUNRISE; Tecan Trading 
AG, Saltzburg, Austria). 
  100(%) Inhibition 540 540540 







 Control
ExtractControl
A
AA
 (2)
3.4. Sugar Loading Test 
Effect on hyperglycemia induced by carbohydrate loads in Sprague-Dawley (SD) rats was evaluated 
by the studying the inhibitory action of GO2KA1, GO2KA2, GO2KA3 and Acarbose on postprandial 
Int. J. Mol. Sci. 2013, 14 14222 
 
 
hyperglycemia. Five week-old male SD rats were purchased from Joongang Experimental Animal Co. 
(Seoul, Korea) and fed a solid diet (Samyang Diet Co., Seoul, Korea) for one week. The rats were 
housed in a ventilated room at 25 ± 2 °C with 50% ± 7% relative humidity, and under an alternating  
12 h light/dark cycle. After six groups of five male SD rats (180–200 g) were fasted for 24 h, 2.0 g/kg 
of sucrose were orally administrated concurrently with 0–500 mg/kg inhibitors (GO2KA1, GO2KA2, 
GO2KA3 and Acarbose). The blood samples were then taken from the tail after administration and 
blood glucose levels were measured at 0, 0.5, 1, and 2 h. The glucose level in blood was determined by 
glucose oxidase method and compared with that of the control group, which had not taken the 
inhibitors. The parameters for blood glucose levels were calculated using WinNonLin program 
(Version 5.2.1, Pharsight Corporation, Cary, NC, USA). Maximum observed peak blood glucose level 
(Cmax) and the time at which it is observed (Tmax) were determined based on the observed data. Area 
under the blood glucose-time curve up to the last sampled time-point (AUClast) was estimated by the 
trapezoidal rule. 
3.5. Statistical Analysis 
All data are presented as mean ± S.D. Statistical analyses were carried out using the statistical 
package SPSS (Statistical Package for Social Science, SPSS Inc., Chicago, IL, USA) program and 
significance of each group was verified with the analysis of One-way ANOVA followed by the 
Duncan’s test of p < 0.05. 
4. Conclusions  
This is the first report of low molecular weight chitosan oligosaccharide mediated α-glucosidase 
inhibition, relevant to type 2 diabetes prevention. Our significant in vitro and in vivo findings indicate 
that enzymatically digested chitosan oligosaccharide has α-glucosidase inhibitory activity, which is not 
molecular weight dependent. Our in vivo observations suggest that all tested samples had significant 
and similar effect on blood glucose management in the tested model. However, GO2KA1, with  
MW < 1000 Da seemed to have a better effect towards postprandial blood glucose management after  
1 h of meal. This observation should not be overlooked and further evaluated. We hypothesize, that 
GO2KA1 with MW below 1000 Da might have “dual” effect towards glucose management by 
inhibiting carbohydrate hydrolysis enzymes, as well as by aiding towards the glucose absorption into 
muscle and fat cells in the cellular level, since it is easier absorbed into the bloodstream (when 
compared to the significantly larger GO2KA2 and GO2KA3). Based on our findings more research 
will be performed towards elucidating the exact mechanism of action of GO2KA1 for type 2 diabetes 
prevention, with focus on the potential insulin sensitizing effect on muscle and fat cells. 
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